Donald L. Hagan LLC Has $74,000 Stake in Scilex Holding (NASDAQ:SCLX)

Donald L. Hagan LLC boosted its position in shares of Scilex Holding (NASDAQ:SCLX) by 32.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 173,292 shares of the company’s stock after purchasing an additional 42,500 shares during the quarter. Donald L. Hagan LLC owned 0.09% of Scilex worth $74,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. State Street Corp lifted its position in shares of Scilex by 0.7% in the third quarter. State Street Corp now owns 7,484,310 shares of the company’s stock worth $6,920,000 after purchasing an additional 54,404 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Scilex by 3.5% during the third quarter. Janus Henderson Group PLC now owns 534,302 shares of the company’s stock worth $494,000 after buying an additional 17,848 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Scilex in the second quarter valued at $25,000. Institutional investors and hedge funds own 69.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on SCLX shares. Alliance Global Partners started coverage on shares of Scilex in a research note on Wednesday, October 16th. They issued a “buy” rating and a $14.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Scilex in a report on Monday, October 21st. Finally, D. Boral Capital initiated coverage on shares of Scilex in a report on Monday. They issued a “buy” rating and a $22.00 target price for the company.

Scilex Price Performance

SCLX stock opened at $0.44 on Friday. Scilex Holding has a 1-year low of $0.38 and a 1-year high of $2.63. The stock’s fifty day simple moving average is $0.50 and its two-hundred day simple moving average is $0.90.

Scilex (NASDAQ:SCLX) last announced its earnings results on Friday, January 17th. The company reported ($0.18) earnings per share for the quarter. On average, equities research analysts forecast that Scilex Holding will post -0.57 earnings per share for the current fiscal year.

Scilex Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.